| 周春晶 刘玉凤 李宏宇 李军 孙秀英 刘奇迹.孟鲁司特钠对哮喘患儿T 淋巴细胞亚群CD4+和CD8+水平的影响[J].,2015,15(19):3671-3673 |
| 孟鲁司特钠对哮喘患儿T 淋巴细胞亚群CD4+和CD8+水平的影响 |
| Effect of Montelukast on the CD4+ and CD8+ Levelsof Patients with Pediatric Asthma |
| |
| DOI： |
| 中文关键词: 孟鲁司特钠 哮喘 CD4+ CD8+ |
| 英文关键词: Montelukast Asthma CD4+ CD8+ |
| 基金项目:国家自然科学基金项目（30671956） |
|
| 摘要点击次数: 701 |
| 全文下载次数: 752 |
| 中文摘要: |
| 目的：探讨孟鲁司特钠联合抗生素对哮喘患儿T 淋巴细胞亚群CD4+和CD8+水平的影响。方法：选取我院收治的哮喘患儿
50 例，并将其随机分为两组，每组各25 例。对照组予常规抗生素治疗，实验组在此基础上加用孟鲁司特钠治疗。观察和比较两组
患儿的临床疗效、一年内复发率，以及CD4+、CD8+和CD4+/CD8+比值的变化情况。结果：两组哮鸣音、咳嗽及喘憋持续时间均获得
改善，实验组优于对照组，差异有统计学意义(P＜0.05)。与同组治疗1 天后比较，两组患儿治疗5、10 天后的CD4+、CD8+以及
CD4+/CD8+比值均明显升高；与同组治疗5 天后比较，两组患儿治疗10 天后CD4+、CD8+以及CD4+/CD8+比值均明显升高；实验
组患儿治疗5 天、10 天后的CD4+、CD8+以及CD4+/CD8+比值均明显高于对照组，差异均有统计学意义(P＜0.05)。两组治疗后
CD4+、CD8+以及CD4+/CD8+比值变化呈显著差异(P＜0.05)。实验组1 年复发率显著低于对照组，差异有统计学意义(P＜0.05)。结
论：孟鲁司特钠可能通过影响哮喘患儿CD4+、CD8+及CD4+/CD8+水平，改善患儿的临床症状，缩短其住院时间，值得临床推广应
用。 |
| 英文摘要: |
| Objective:To investigate the effect of montelukast sodium combined with antibiotics on the T lymphocyte subsets
CD4+ and CD8+ levels of asthmatic children.Methods:50 children with asthma admitted in our hospital were selected and randomly
divided into two groups with 25 cases in each group. The control group was treated with conventional antibiotics, while the experimental
group was treated with the reduning on the basis of the control group. Then the clinical efficacy, recurrence rate within 1 year, and the
changes of CD8+, CD4+ levels as well as ratio of CD4+/CD8+ were compared between two groups.Results:Wheeze, cough and asthma
duration were improved, in both groups and the experimental group was better than the control group (P<0.05). The CD4+, CD8+ levels
and CD4+/CD8+ ratio were significantly increased after 5, 10 days’treatment compared with those on the 1st day of treatment. The CD4+,
CD8+ levels and CD4+/CD8+ ratio were significantly increased after 10 days’treatment compared with those after 5 days’treatment. The
CD4+, CD8+ levels and CD4+/CD8+ ratio of experimental group were significantly higher than those of the control group after 5 days’and
10 days’treatment (P<0.05). Significant differences were found in CD4+, CD8+ levels and CD4+/CD8+ ratio between the two groups after
treatment (P<0.05). The 1 year recurrence rate of experiment group was significantly lower than that of the control group (P<0.05).Conclusion:Montelukast could improve the CD4+ and CD8+levels, restore the immune system function and promote the clinical effect
of children with asthma. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
